ASCO Lung Cancer Highlights, Part 13: The Immune Checkpoint Inhibitor MPDL3280A in Advanced NSCLC (audio)
09/04/13 • 5 min
Dr. Edward Garon, David Geffen School of Medicine at UCLA, covers the provocative results of the novel immune checkpoint PD-L1 inhibitor MPDL3280A in advanced NSCLC.
Dr. Edward Garon, David Geffen School of Medicine at UCLA, covers the provocative results of the novel immune checkpoint PD-L1 inhibitor MPDL3280A in advanced NSCLC.
Previous Episode
ASCO Lung Cancer Highlights, Part 12: Ganetespib with Second Line Chemotherapy for Advanced NSCLC (video)
Dr. Edward Garon, David Geffen School of Medicine at UCLA, reviews impressive results from the GALAXY-1 trial of the heat shock protein inhibitor ganetespib combined with combined with second line docetaxel in advanced lung adenocarcinoma.
Next Episode
ASCO Lung Cancer Highlights, Part 13: The Immune Checkpoint Inhibitor MPDL3280A in Advanced NSCLC (video)
Dr. Edward Garon, David Geffen School of Medicine at UCLA, covers the provocative results of the novel immune checkpoint PD-L1 inhibitor MPDL3280A in advanced NSCLC.
If you like this episode you’ll love
Episode Comments
Generate a badge
Get a badge for your website that links back to this episode
<a href="https://goodpods.com/podcasts/gracecast-97807/asco-lung-cancer-highlights-part-13-the-immune-checkpoint-inhibitor-mp-13138420"> <img src="https://storage.googleapis.com/goodpods-images-bucket/badges/generic-badge-1.svg" alt="listen to asco lung cancer highlights, part 13: the immune checkpoint inhibitor mpdl3280a in advanced nsclc (audio) on goodpods" style="width: 225px" /> </a>
Copy